

**This Page Is Inserted by IFW Operations
and is not a part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.


Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Figure 1.




wherein

R^1 , R^2 and R^3 are each independently of the others an aliphatic hydrocarbon radical having from 7 to 21 carbon atoms,

n is 0 or 1,

As is the amidically bonded residue of a (D)- or (L)-amino acid or of a (D)- or (L)-amino acid derivative from the group consisting of Gly, Ala, Ser, Thr, Asp, Asp(R^5), Glu, Glu(R^5), Glu, Glu(R^5) and Glu(R^5)₂, and

R^4 and R^5 are each independently of the other the amidically bonded radical of an unsubstituted or carboxy-substituted ω -amino-C₂-C₃alkanesulfonic acid.

[illegible]




Figure 3





Figure 4

MLV-JT3

(A)

133

71



42

31

kDa

β -actin

- 10' 20' 30' 4h 24h



IFN γ
LPS
MLV-JT3002

(B)

133

71

42

31

kDa

β -actin

+ + - + + + + +
- 15' - - - - -
- - - 5' 10' 20' 30' 120'




Figure 5







Figure 6

Downloaded from www.jci.org on June 10, 2015. For personal use only. All rights reserved. No part of this publication may be reproduced without prior written permission from the American Society for Clinical Investigation.




Figure 7




Figure 8




Figure 9




Figure 10




Figure 11




Figure 12




Figure 13





Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19

COPY

CONFIDENTIAL

PBS followed by CPT-11

Oral MTP-PE followed by CPT





Figure 20

COPY CONFIDENTIAL




Figure 21

ILEUM


Control

CPT-11


JBT3002

JBT3002/CPT-11


H & E



BrdUrd



IL-15



IL-15 RT-PCR




Fig 23